• LAST PRICE
    5.9400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    5.7800/ 1
  • Ask / Lots
    6.2700/ 1
  • Open / Previous Close
    --- / 5.9400
  • Day Range
    ---
  • 52 Week Range
    Low 3.0500
    High 9.0100
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 5.98
TimeVolumeABEO
09:32 ET19626.06
09:33 ET74006.075
09:35 ET25176.145
09:37 ET17006.145
09:39 ET2006.17
09:42 ET15066.17
09:44 ET12106.12
09:46 ET105666.07
09:48 ET8006.095
09:50 ET1006.11
09:51 ET2006.095
09:53 ET20476.04
09:57 ET61756.002
10:02 ET1006.025
10:04 ET24816.0399
10:11 ET1006.055
10:13 ET19826.05
10:15 ET24916.065
10:18 ET1006.075
10:20 ET10006.0792
10:22 ET1236.072
10:24 ET1006.085
10:27 ET34236.06
10:29 ET2006.065
10:31 ET1006.075
10:33 ET7006.074
10:36 ET20756.06
10:38 ET2006.065
10:40 ET3016.065
10:42 ET1016.065
10:44 ET3006.065
10:45 ET7066.06
10:47 ET8986.065
10:51 ET3966.05
10:54 ET9006.05
10:56 ET1006.045
10:58 ET3006.066
11:02 ET10556.03
11:03 ET1006.045
11:07 ET8006.045
11:12 ET3006.025
11:20 ET3006.035
11:25 ET9006.02
11:32 ET15136.01
11:34 ET6776.01
11:36 ET6486
11:38 ET12215.99
11:39 ET1006.005
11:41 ET1006.005
11:45 ET4816.01
11:48 ET7986
11:54 ET6886.01
11:56 ET2256.0102
11:57 ET1006.015
11:59 ET11006.03
12:03 ET5006.04
12:06 ET3006.03
12:10 ET4366.029
12:14 ET15746.02
12:15 ET39306.01
12:17 ET7486.03
12:19 ET39266.06
12:21 ET3016.045
12:24 ET1006.03
12:26 ET1006.05
12:28 ET5006.04
12:30 ET3006.04
12:32 ET13006.03
12:33 ET3006.0217
12:37 ET1006.035
12:44 ET1006.04
12:46 ET5006.05
12:48 ET3006.03
12:51 ET1006.04
12:53 ET2006.04
01:00 ET6906.05
01:02 ET1026.05
01:04 ET1006.05
01:08 ET42406.05
01:11 ET2016.055
01:13 ET4016.055
01:15 ET2006.055
01:18 ET44606.05
01:22 ET6006.05
01:24 ET18006.045
01:26 ET5766.045
01:27 ET5006.045
01:29 ET12006.04
01:40 ET3006.045
01:47 ET7706.05
01:49 ET2006.04
01:51 ET12036.025
02:02 ET1006.025
02:05 ET1006.025
02:07 ET5416.03
02:09 ET1006.035
02:14 ET28326.045
02:16 ET63036.05
02:20 ET11006.035
02:25 ET11096.02
02:32 ET1006.02
02:36 ET1006.02
02:38 ET1006.02
02:39 ET12006.01
02:41 ET3006
02:45 ET2386.01
02:48 ET14876.015
02:50 ET1006.015
02:54 ET14005.984
02:57 ET9005.97
02:59 ET1005.97
03:01 ET1005.96
03:03 ET1005.965
03:06 ET1005.96
03:08 ET3005.975
03:10 ET1005.98
03:19 ET11005.98
03:21 ET6005.98
03:24 ET4005.98
03:28 ET1005.98
03:33 ET3005.995
03:35 ET6086
03:42 ET1006
03:44 ET5006
03:46 ET52855.96
03:48 ET7005.96
03:50 ET15265.97
03:51 ET2135.97
03:53 ET8205.97
03:55 ET7155.97
03:57 ET25845.965
04:00 ET63895.94
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesABEO
Abeona Therapeutics Inc
260.0M
-2.6x
---
United StatesOCGN
Ocugen Inc
264.3M
-5.0x
---
United StatesATYR
aTyr Pharma Inc
254.3M
-3.3x
---
United StatesTVGN
Tevogen Bio Holdings Inc
256.0M
3.8x
---
United StatesLYEL
Lyell Immunopharma Inc
265.3M
-1.1x
---
United StatesATAI
ATAI Life Sciences NV
270.2M
-2.1x
---
As of 2024-11-26

Company Information

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Contact Information

Headquarters
6555 CARNEGIE AVE, 4TH FLOORCLEVELAND, OH, United States 44103
Phone
646-813-4701
Fax
302-655-5049

Executives

Chairman of the Board
Michael Amoroso
President, Chief Executive Officer, Director
Vishwas Seshadri
Chief Financial Officer
Joseph Vazzano
General Counsel
Brendan O Malley
Independent Director
Leila Alland

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$260.0M
Revenue (TTM)
$0.00
Shares Outstanding
43.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.42
EPS
$-2.29
Book Value
$0.56
P/E Ratio
-2.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.